机构观点机构舆情整体中性，暂无近期评级调整。根据4家机构预测，2025年公司净利润预计同比增长 23.62%，营收微增0.94%；2026年净利润增速料达20.22%。当前市盈率（TTM）为34.02倍，高于行业 平均水平，需关注新业务转型进展对盈利的支撑作用。 经济观察网 武商集团董事兼总经理秦琴因达到法定退休年龄申请辞去相关职务，辞职即日生效。秦琴 未持有公司股份，且离任不会影响董事会正常运作，公司后续将按程序补选董事及聘任高管。该人事变 动涉及核心管理层，可能引发市场对公司治理稳定性的关注。 以上内容基于公开资料整理，不构成投资建议。 股票近期走势近7日（2026年2月24日至27日），武商集团股价震荡上行，区间涨幅1.99%，最高价9.77 元，最低价9.53元。2月27日最新收盘价9.72元，单日微涨0.10%，成交金额5084万元，换手率0.68%。 资金流向显示当日主力净流入337.46万元，但20日累计跌幅仍达10.08%，短期表现弱于大盘（上证指数 同期涨0.39%）。新零售板块同期涨0.55%，公司股价略低于板块涨幅。 ...

Investment Rating - Industry Rating: Outperform the Market (maintained rating) [4] Core Insights - The pharmaceutical raw material sector showed a preliminary trend of marginal stabilization and recovery in Q1 2025, with key characteristics including the stabilization of raw material prices, integration of formulations, and the transition to new business models [1][2][3] Summary by Sections Raw Material Prices - After a year of continuous price decline in 2024, some raw material prices in Q1 2025 have shown signs of stabilization, with year-on-year declines but month-on-month increases for certain products. Companies have indicated that products with significant price drops in 2024 are stabilizing or increasing in price in 2025. The overall theme for 2024 was to exchange price for volume, while 2025 is expected to enter a phase of stable prices and increased volume [1] Formulation Integration - Companies like Tianyu Co. have experienced growth in Q1, partly due to the expansion of formulation product lines and the renewal of national procurement contracts. For companies with annual revenue below a certain threshold (e.g., 500 million), the rapid growth of formulation business is expected to significantly contribute to profits within the next 2-3 years [2] New Business Transition - Traditional raw material business margins have been shrinking due to intense competition. Therefore, expanding into innovative businesses is essential for the transformation of raw material companies. Companies are beginning to see returns from new business ventures, such as innovative drugs and complex formulations, with examples including Huahai Pharmaceutical's new monoclonal antibodies and Aorite's small nucleic acid technology platform [3]